WO2000067743A1 - Phagocyte radicalaire - Google Patents
Phagocyte radicalaire Download PDFInfo
- Publication number
- WO2000067743A1 WO2000067743A1 PCT/JP2000/002908 JP0002908W WO0067743A1 WO 2000067743 A1 WO2000067743 A1 WO 2000067743A1 JP 0002908 W JP0002908 W JP 0002908W WO 0067743 A1 WO0067743 A1 WO 0067743A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- erythritol
- radical scavenger
- present
- radicals
- Prior art date
Links
- 239000002516 radical scavenger Substances 0.000 title claims abstract description 38
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 56
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 56
- 239000004386 Erythritol Substances 0.000 claims abstract description 55
- 235000019414 erythritol Nutrition 0.000 claims abstract description 55
- 229940009714 erythritol Drugs 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000001301 oxygen Substances 0.000 claims abstract description 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims description 14
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 7
- 229940118019 malondialdehyde Drugs 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- -1 superoxide ionone Chemical class 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000004435 EPR spectroscopy Methods 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 235000003891 ferrous sulphate Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 235000014214 soft drink Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000009627 gardenia yellow Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 2
- 238000013319 spin trapping Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000025467 Gastrointestinal mucosal disease Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229940010514 ammonium ferrous sulfate Drugs 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229930002839 ionone Natural products 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the present invention relates to a radical scavenger containing erythritol, which can be used in the fields of medicine, food, cosmetics and the like.
- Radicals in the body include radicals generated as metabolic intermediates of the redox system, and radicals generated by radiation or ultraviolet light. Typical radicals include superoxide ionone (0 2 â) It is known that active oxygen such as hydroxyl radical ( â 0 â ) exists. Reactive oxygen plays an essential role in the biosynthesis and gene expression of hormones, in addition to the important defense mechanism of the organism against viruses and pathogens, but it also plays an essential role in hormone biosynthesis and gene expression.
- hydroxyl radicals may themselves or active oxygen is a radical, active oxygen is a source of radicals as hydrogen peroxide and singlet oxygen 0 2) is excessively occurred, lipids, proteins, nucleic acids It is known that it reacts with such biological components as to cause damage to cell membranes, protein degeneration, gene mutation, etc., resulting in damage to biological functions and various diseases such as cancer and aging.
- Disorders in which the involvement of reactive oxygen species have been pointed out include, for example, inflammatory cell damage, diabetic diseases (nephropathy, retinopathy, neuropathy), atherosclerosis, Alzheimer's disease, Parkinson's disease, cancer, ischemiaâ Examples include reperfusion injury, renal failure, and myocardial infarction (Hogg, N. Free Radicals in Disease: Seminars in Reproductive Endocrinology, vol. 16, No. 4, 1998).
- a substance having such a property of capturing and stabilizing a radical in a living body (this property is sometimes referred to as âradical scavenging abilityâ in this specification) is called a radical scavenger.
- enzymes such as superoxide desmutase, glucan thion peroxidase, and power cod, pyrirubin, uric acid, Vitamin E and carotenoids are known to act as radical scavengers.
- isoflavonoids, phenols, and ascorbic acid are known to have a scavenging effect on active oxygen among reagents other than biological substances (Nagano et al., Pharmacia, 27, pp.231-233, 1991).
- JP-T-61-502821 discloses that sugar alcohols, specifically, mannitol, sorbitol, and xylitol can be used as hydroxyl radical scavengers, but erythritol has a radical scavenging ability. Is not stated. Also, Japanese Patent Application Laid-Open No. 11-124310 describes that a polyhydric alcohol such as erythritol suppresses phototoxicity due to active oxygen and free radicals, but this publication does not suggest a mechanism of the above-mentioned inhibitory action. There is no teaching and no indication of the radical scavenging ability of erythritol. Disclosure of the invention
- An object of the present invention is to efficiently exhibit a radical scavenging ability against radicals in a living body, particularly hydroxyl radicals having the highest reaction rate in active oxygen and having no removing mechanism in the living body.
- An object of the present invention is to provide a radical scavenger that can be used for an active ingredient of a medicine, an additive for a pharmaceutical preparation, a preservative of a biological sample, or a food, a food additive, a cosmetic, or the like.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, the non-metabolizable and easily absorbed and easily excreted properties of erythritol can efficiently eliminate radicals in a living body, thereby ensuring safety. And useful as an effective radical scavenger.
- the present invention has been completed based on the above findings.
- the present invention provides a radical scavenger containing erythritol.
- the above radical scavenger wherein the radical to be trapped is active oxygen, preferably a hydroxyl radical.
- the radical scavenger of the present invention may be used as a pharmaceutical active ingredient, a pharmaceutical additive used for pharmaceutical preparation, a biological sample preservative, a food, a food additive, or a cosmetic. It can be used for such purposes.
- the medicament containing the radical scavenger of the present invention as an active ingredient is useful for prevention and / or treatment of a disease involving a radical in a living body.
- the present invention provides a method of using erythritol as a radical scavenger; a method for scavenging radicals in a living body, comprising a step of administering an effective amount of erythritol to a mammal including human. And a method for preventing and / or treating a disease involving an in vivo radical, which comprises administering a prophylactically and / or therapeutically effective amount of erythritol to mammals including humans. . BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a diagram showing the results of measuring the hydroxyl radical scavenging ability of the radical scavenger of the present invention by an electron spin resonance (ESR) spin trap method.
- ESR electron spin resonance
- the spectrum on the left shows the results for erythritol (the present invention), and the spectrum on the right shows the results for glucose (control).
- the two peaks on the left and right indicate manganese power, and the four peaks in the center indicate DMP0-0H.
- Erythritol (erythritol: sometimes referred to as erythritol, erythritol or erythritol) used in the present invention is meso-erythritol, and a commercially available sweetener may be used. it can.
- the utilization form of the radical force avenger of the present invention is not particularly limited, and it can be used for various kinds of radicals in vivo and in vitro.
- Radicals of the present invention scavengers that can be scavenged include active oxygens such as superoxydione (0 2 â), hydroxyl radical ( â 0 â ), hydroperoxy radical ( â 00 â ), and lipid peroxy. Examples include, but are not limited to, xyl radicals and lipid alkoxy radicals.
- Active oxygen is a preferred scavenger for the radical scavenger of the present invention.
- a particularly preferred eraser is hydroxylradica It is.
- erythritol as an active ingredient can be administered orally or parenterally.
- Parenteral administration includes administration routes such as intra-airway, rectum, subcutaneous, intramuscular, intravenous, and eye drops.
- Erythritol can be administered alone as a medicament, but a pharmaceutical composition in an appropriate form may be produced and administered using a pharmaceutical additive together with erythritol.
- Pharmaceutical compositions suitable for oral administration include, for example, tablets, granules, fine granules, powders, syrups, solutions, capsules, suspensions and the like.
- preparations suitable for parenteral administration include injections, drops, inhalants, sprays, suppositories, transdermal absorbers, transmucosal absorbers, and the like.
- erythritol may be compounded as a medicine in drinks, health drinks, soft drinks, health foods, and the like.
- Pharmaceutical additives include, for example, stabilizers, surfactants, plasticizers, lubricants, solubilizers, buffers, sweeteners, bases, adsorbents, corrigents, binders, suspending agents , Brightener, coding agent, flavoring agent, fragrance, humectant, wetting regulator, filler, defoamer, chewing agent, freshener, coloring agent, sugar coating, tonicity agent, pH regulator, Softeners, emulsifiers, adhesives, adhesion enhancers, thickeners, thickeners, foaming agents, excipients, dispersants, propellants, disintegrants, disintegration aids, fragrances, moisture inhibitors, preservatives , A preservative, a soothing agent, a solvent, a solubilizer, a solubilizer, a fluidizer, and the like.
- a pharmaceutical composition in a desired form can be produced by selecting a pharmaceutical additive according to the method described above and according to a method commonly used in the art.
- the medicament containing the radical scavenger of the present invention as an active ingredient is useful for prevention and / or treatment of various diseases related to in vivo radicals.
- active oxygen-related diseases include, for example, brain, neurological diseases (Alzheimer's disease, Parkinson's disease, cerebrovascular disorder, etc.), lung diseases (pulmonary oxygen poisoning, respiratory distress syndrome, Airway hyperreactivity), myocardial ischemia-reperfusion injury, myocardial infarction, vascular disease (arteriosclerosis, etc.), gastrointestinal mucosal disorder (gastrointestinal ulcer, etc.), liver disease, kidney disease (nephritis, renal failure, etc.), eye disease Patients (cataracts, retinal diseases, etc.), skin diseases (dermatitis, photosensitivity, etc.), diabetic diseases, immune diseases (AIDS, autoimmune diseases, etc.), and cancer.
- the medicament of the present invention is useful for preventing and / or treating these diseases.
- the medicament of the present invention can be used as an anti-related diseases.
- the dose and frequency of administration of the medicament are not particularly limited, and are appropriately determined according to various conditions such as the type of disease to be prevented and / or treated, the administration route, the age and weight of the patient, the symptoms, and the severity of the disease. It is possible to choose. For example, weight per adult day
- the medicament of the present invention can be used in combination with an active ingredient of another medicament.
- the radical scavenger of the present invention as a pharmaceutical additive, it is possible to prevent a decrease in the amount of the active ingredient due to the reaction between the active ingredient of the drug and the active oxygen radical, and to improve the stability of the preparation against light and heat. Can be enhanced. In general, it is preferable to produce a pharmaceutical composition using one or more of the above-mentioned pharmaceutical additives and the radical scavenger of the present invention together with the active ingredient of the pharmaceutical.
- the amount of the radical scavenger of the present invention when used as an additive for pharmaceutical preparations is not particularly limited, and an appropriate amount can be determined according to the type of active ingredient drug and the form of preparation. Is about 0.1 to 1,000 times the weight of the active ingredient of the medicament.
- the radical scavenger of the present invention can also be used as a preservative for a biological sample separated and collected from a living body.
- Biological samples include, but are not limited to, blood, urine, etc., as well as pathological tissues and excised tissues for examination.
- by adding the radical scavenger of the present invention to a blood collection tube in advance it is possible to eliminate the influence of active oxygen on a blood sample, Reliable clinical tests and diagnoses become possible.
- the radical scavenger of the present invention By incorporating the radical scavenger of the present invention into foods or cosmetics, it is possible to prevent deterioration of the quality of foods or cosmetics due to radicals such as active oxygen.
- foods include fresh foods such as vegetables, meats, fish, and cereals, as well as processed foods such as cooked foods, sweets, low-calorie sweet compositions, and soft drinks. It can also be blended as an antioxidant for edible oils.
- the type of fresh food or processed food is not particularly limited, and it can be blended in various foods.
- the radical scavenger of the present invention can be particularly suitably blended with foods to which sweetness is preferably added, for example, jam, milk, yogurt, chewing gum, soft drinks, and the like.
- Erythritol which is an effective component of the radical scavenger of the present invention, is hardly metabolized in vivo and easily absorbed in the gastrointestinal tract when administered orally (Oku T., Recent Res. Devel., Nutrition , 1, pp. 1-13, 1996). Therefore, it is advantageous when used for eliminating radicals in a living body.
- the examples of the present specification disclose in detail a method for testing the radical scavenging ability of the radical scavenger of the present invention, and those skilled in the art will be able to refer to the specific description of the examples to understand the present invention.
- the radical scavenger of the present invention is used for various purposes such as an active ingredient of a medicine, a pharmaceutical additive, a preservative of a biological sample, a food, a food additive, or a cosmetic, an appropriate amount can be easily determined. It is possible.
- the ability of the radical scavenger of the present invention to scavenge hydroxyl radicals The W ribose method (Hall iwell, FEBS Lett., 128, pp. 347-352, 1981) was partially modified and examined. Heating malondialdehyde (MDA) from the reaction of hydroxyl radical with deoxyribose at low pH with thionorebituric acid produces a colored product. MDA generation is suppressed. In this test method, the amount of inhibition of MDA production in the presence or absence of erythritol was determined, and the ability of erythritol to scavenge hydroxyradiradil was examined.
- MDA malondialdehyde
- reaction mixture Prepare the reaction mixture to a final concentration of 50 mM phosphate buffer (pH 7.0), 60 mM NaCU, and 10 mM deoxyribose, and add erythritol to final concentrations of 0.05%, 0.5%, and 5%.
- ammonium ferrous sulfate was added finally to 25 â M, and reacted at 37 ° C for 15 minutes.
- 1 ml of 0.6% thiobarbituric acid and 1 ml of 3.5% trichloroacetic acid were added to 1 ml of the reaction solution, and the mixture was stirred and heated at 100 ° C for 10 minutes.
- the reaction solution was cooled with water for 10 minutes, and the absorbance at 532 nm was measured.
- the MDA generation inhibition rate (%) was calculated by the following equation: 100 â â(absorbance (with erythritol added) â absorbance (without erythritol) x 100 â .
- the inhibition rate of MDA was 44.6% at the erythritol 0.05 concentration, the inhibition rate was 81.8% at the 0.5% concentration, and the inhibition rate was 88.4% at the 5th crop.Erythritol reduced the hydroxyl radical at a concentration of 0.5% or more. It was clear that the erasure was almost complete.
- the inhibition rate of MDA production was measured using glucose as a control. The inhibition rate was 21.6% at 0.05% concentration, 64.3% at 0.5 concentration, and 59.9% at 5% concentration.
- Example 2 Hydroxyl radical scavenging ability
- Linoleic acid was added to 30 mM (pH 11) with stirring, adjusted to pH 7 with INHC1, and 2.8 mg / ml (10 mM) micelles were prepared. After adding 1 mL of 0.8% Lubrol PX (Sigma) to 1 mL of the micelle, the total volume was adjusted to 10 mM with 30 mM NaCl (pH 7) and used as 1 mM micelle.
- each test substance final concentration was added in a volume of 20 â 100 â L so that l â 50 mM, was further added 10 mM H 2 0 2 20 â L.
- 16 mM FeCl 2 10 / LL was added to induce the peroxidation reaction of linoleic acid, and the progress of the reaction was determined with the passage of time as the generation of conjugated gen.
- the change in absorbance at 234 nm was measured using a spectrophotometer (Hitachi, Model 557 Next wavelength spectrophotometer). The reaction was performed at 37 ° C.
- the control was prepared by adding distilled water in place of the test substance, and the decrease in absorbance when the absorbance of the control was set to 100 was defined as the inhibition rate of the test substance.
- the inhibition rate was 3.4% at 1 mM erythritol, 18.0% at 5 mM, 18.2% at 10 # 1, and 26.6% at 50 mM.
- Example 3 Gardenia yellow stabilization
- the effect of erythritol on dye stabilization was examined.
- the residual ratio of the dye was measured by irradiating a fluorescent lamp (3,000 lux) at room temperature in the presence or absence of 10% erythritol.
- the dye concentration was set to 0.05, and the pH of the reaction mixture was adjusted with 0.01 M citrate-monocitrate buffer.
- the residual dye ratio was calculated by measuring the absorbance at the maximum absorption wavelength of 440 nm, and setting the absorbance at the start to 100, using the following formula. (Absorbance â absorbance at start) X 100
- the residual dye ratio at PH3.5 was 60.0% after 1 day, and 35.0% after 2 days. In the absence of erythritol, it was 46.2% after 1 day and 20.8% after 2 days (residual rate after light shielding was 89.0% after 1 day and 79.2% after 2 days). In the presence of erythritol, the residual ratio of the pigment was 71.6% after 10 days and 48.5% after 20 days. The residual dye rate in the absence of erythritol was 10 57.9% after 20 days and 29.5% after 20 days (residual rate after shading was 91.1 ° after 20 days and 79.0% after 20 days).
- the residual ratio of riboflavin in the presence of erythritol was 36.8%, and the residual ratio of riboflavin in the absence of erythritol was 13.1%. (The residual ratio under light shielding was 104.0%.) The residual ratio was calculated from the following formula by measuring the absorbance at the maximum absorption wavelength of 450 nm.
- the ability of the radical scavenger of the present invention to scavenge hydroxyl radicals was examined by electron spin resonance (ESR) spin trapping.
- ESR electron spin resonance
- the hydroxyl radical generated by the Fenton reaction (H 2 0 2 + Fe 2+ â '0H + 0H- + Fe 3+ ) was converted to 5,5-dimethyl-topyroline-N-oxide (DMP0) as a spin trapping agent.
- DMP0 5,5-dimethyl-topyroline-N-oxide
- the hydroxyl radical scavenging rate (%) was calculated from the following equation: 100â â (DMP0-0H spectrum peak height due to erythritol addition â manganese marker peak height) X100 â ( The peak height of the DMP0-0H spectrum without the addition of erythritol (the peak height of the manganese marker) X100 â .
- a similar test was performed using glucose as a control. The results are shown in Figure 1.
- the spectrum intensity of DMP0-0H was suppressed at 49.1% at 0.01% erythritol concentration, 71.4% at 0.05% concentration, 81.9% at 0.1% concentration, and 92.1% at 0.5% concentration, which is remarkable compared to glucose. Radical scavenging ability was observed.
- Example 6 Radical scavenging ability in neutrophil viability
- the radical force avenger of the present invention can efficiently eliminate radicals such as active oxygen.
- Erythritol is almost an energy source in the human body. Since it is not used and has properties of easy absorption and excretion, it is circulated in the blood and acts as a radical scavenger, and then excreted outside the body. Therefore, the radical callus venger of the present invention can be used as an active ingredient of a medicine, a pharmaceutical additive, a food additive, a health food, a cosmetic, or the like.
Description
æ 现 æž ã©ãžã«ã«ã¹ã«ãã³ãžã£äž
æè¡åé
æ¬çºæã¯ã ãšãªã¹ãª ããŒã«ãå«ã¿ã å»è¬ã é£åã åã¯å粧åãªã©ã®åéã«ãã ãŠå©çšå¯èœãªã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã«é¢ãããã®ã§ããã èæ¯æè¡
çäœå
ã©ãžã«ã«ãšããŠã é
žåéå
ç³»ã®ä»£è¬äžéäœãšããŠçæããã©ãžã«ã«ãã æŸå°ç·åã¯çŽ«å€ç·ãªã©ã«ãã£ãŠçããã©ãžã«ã«ãªã©ãååšããŠããã 代衚çãªã© ãžã«ã«ãšããŠã ã¹ãŒããŒã©ãã·ãã¢äºãªã³ïŒ02â )ã ã ãããã·ã«ã©ãžã«ã«ïŒÎ0· )㪠ã©ã®æŽ»æ§é
žçŽ ã®ååšãç¥ãããŠããã 掻æ§é
žçŽ ã¯ã ãŠã£ã«ã¹ãç
åèã«å¯Ÿããç äœã®éèŠãªé²åŸ¡æ©æ§ã®ã»ãã ã¹ãŒããŒã©ãã·ãã¢äºãªã³ãªã©ããã«ã¢ã³ã®çåæ ãéºäŒåçºçŸã«å¿
é ã®åœ¹å²ãæãããŠãããã ãã®åé¢ã ã¹ãŒãäžã©ãã·ãã¢äº ãªã³ãããããã·ã«ã©ãžã«ã«ã®ããã«ã ããèªäœãã©ãžã«ã«ã§ãã掻æ§é
žçŽ ãã éé
žåæ°ŽçŽ ãäžéé
é
žçŽ 02)ã®ããã«ã©ãžã«ã«ã®çºçæºãšãªã掻æ§é
žçŽ ãéå° ã«çããå Žåã è質ã èçœè³ªã æ žé
žãªã©ã®çäœæåãšåå¿ããŠçŽ°èèã®æå·ã è çœè³ªã®å€æ§ã éºäŒåå€ç°ãªã©ãåŒãèµ·ããã ãã®çµæã çäœæ©èœãæå·ãããŠç ãªã©ã®æ§ã
ãªçŸæ£ãèåãçããããšãç¥ãããŠããã 掻æ§é
žçŽ ã®é¢äžãææã ããŠããçŸæ£ãšããŠã¯ã äŸãã°ã ççæ§ã®çŽ°èé害ã ç³å°¿ç
æ§çŸæ£ ïŒè
çã 網è çã ç¥çµé害ïŒã ã¡ãããŒã 硬åã ã¢ã«ããã€ããŒçã ããŒãã³ãœã³ç
ã çã èè¡ âåçæµé害ãè
äžå
šãå¿çæ¢å¡ãªã©ããã ïŒHoggïŒ N. Free Radicals in Disease : Seminars in Reproductive Endocrinology, vol .16, No. 4ïŒ 1998)ã
ãã®ãããªçäœå
ã©ãžã«ã«ãææããŠå®å®åãããæ§è³ª ïŒæ¬æ现æžã«ãããŠã ãã®æ§è³ªã ãã©ãžã«ã«æ¶å»èœã ãšåŒã¶ããšããããïŒ ããã€ç©è³ªã¯ã ã©ãžã«ã«ã¹ã« ãã³ãžã£ãŒãšåŒã°ããŠããã çäœå
ç©è³ªã®ãªãã§ã¯ã¹ãŒãäžã©ãã·ããã¹ã ã¿ãŒ ãŒã ã°ã«å€ããªã³ãã«ã©ãã·ãäžãŒã åã¿ã©äžãŒãªã©ã®é
µçŽ ã ããªã«ãã³ãå°¿é
žã
ãã¿ãã³ Eã ã«ããã㣠ããªã©ãã©ãžã«ã«ã¹ã«ãã³ãžã£äžãšããŠäœçšããããšã ç¥ãããŠããã ãŸãã çäœå
ç©è³ªä»¥å€ã®è©Šè¬ã§ã¯ã ã€ãœãã©ãã〠ãã ããšã㌠ã«é¡ã ã¡ã¹ã³ã«ãã³é
žãªã©ã掻æ§é
žçŽ ã«å¯ŸããŠæ¶å»äœçšãæããããšãç¥ãã㊠ãã ïŒé·éãïŒ ãã¢ã«ãã·ã¢ïŒ 27, pp.231-233, 1991 )ã
ãªããç¹è¡šæ 61-502821å·å
¬å ±ã«ã¯ãç³ã¢ã«ã³ãŒã«ãå
·äœçã«ã¯ãã³ãããŒã«ã ãœã«ãããŒã«ã åã³ãã·ãª ããŒã«ãããããã·ã«ã©ãžã«ã«æç²å€ãšããŠäœ¿çšã§ã ãããšãèšèŒãããŠãããã ãšãªã¹ãª ããŒã«ãã©ãžã«ã«ææèœãæããããšã¯èš èŒãããŠããªãã ãŸãã ç¹éå¹³ 11-124310å·å
¬å ±ã«ã¯ãšãªã¹ãª ããŒã«ãªã©ã®å€äŸ¡ ã¢ã«ã³ãŒã«ã掻æ§é
žçŽ · ããªãŒã©ãžã«ã«ã«ããå
æ¯æ§ãæå¶ãããšèšèŒãããŠã ããã ãã®åè¡ç©ã«ã¯äžèšæå¶äœçšã®æ©åºã«ã€ããŠç€ºåãªããæ瀺ã¯ãªãã ãšãª ã¹ãª ããŒã«ã®ã©ãžã«ã«æ¶å»èœã¯ç€ºåãããŠããªãã çºæã®é瀺
æ¬çºæã®èª²é¡ã¯ã çäœå
ã©ãžã«ã«ã ç¹ã«ã 掻æ§é
žçŽ äžã§æãé«ãåå¿é床ãæ ãã çäœå
ã«é€å»æ©æ§ã®ãªãããããã·ã«ã©ãžã«ã«ãªã©ã«å¯ŸããŠå¹ççã«ã©ãžã« ã«æ¶å»èœãçºæ®ããããšãã§ãã å»è¬ã®æå¹æåã å»è¬ã®è£œå€çšæ·»å ç©ã çäœè©Š æã®ä¿åå€ã åã¯é£åã é£åæ·»å ç©ã å粧åãªã©ã«å©çšå¯èœãªã©ãžã«ã«ã¹ã«ãã³ ãžã£ãŒãæäŸããããšã«ããã
æ¬çºæè
ãã¯äžèšã®èª²é¡ã解決ãã¹ãéæç 究ãè¡ã£ãçµæã ãšãªã¹ãª ããŒã« ã®é代è¬æ§ã§æåžååã³æææ³ã®ç¹æ§ã«ããã çäœå
ã®ã©ãžã«ã«ãå¹ççã«æ¶å» ããããšãã§ãã å®å
šã§å¹æçãªã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãšããŠæçšã§ããããš ãèŠåºããã æ¬çºæã¯ã äžèšã®ç¥èŠãåºã«ããŠå®æããããã®ã§ããã
ããªãã¡ã æ¬çºæã¯ã ãšãªã¹ãª ããŒã«ãå«ãã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãæäŸã ããã®ã§ããã æ¬çºæã®å¥œãŸããæ
æ§ã«ããã°ã ææ察象ãšãªãã©ãžã«ã«ãæŽ»æ§ é
žçŽ ã 奜ãŸããã¯ããããã·ã«ã©ãžã«ã«ã§ããäžèšã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãæ äŸãããã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã¯ã å»è¬ã®æå¹æåã å»è¬ã®è£œå€ã® ããã«çšãã補å€çšæ·»å ç©ã çäœè©Šæã®ä¿åå€ã é£åã é£åæ·»å ç©ã åã¯å粧å
ãªã©ã®çšéã«çšããããšãã§ããã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãæå¹æå ãšããŠå«ãå»è¬ã¯ã çäœå
ã©ãžã«ã«ãé¢äžããçŸç
ã®äºé²åã³/åã¯æ²»çã«æçš ã§ããã
å¥ã®èŠ³ç¹ããã¯ã æ¬çºæã«ããã ãšãªã¹ãª ããŒã«ã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãš ããŠã®äœ¿çšïŒçäœå
ã©ãžã«ã«ã®æ¶å»æ¹æ³ã§ãã£ãŠã æå¹éã®ãšãªã¹ãª ããŒã«ãã ããå«ãåºä¹³é¡åç©ã«æäžããå·¥çšãå«ãæ¹æ³ïŒåã³ã çäœå
ã©ãžã«ã«ãé¢äžã ãçŸç
ã®äºé²åã³/åã¯æ²»çæ¹æ³ã§ãã£ãŠã äºé²åã³/åã¯æ²»çæå¹éã®ã§ãªã¹ 㪠ããŒã«ããããå«ãåºä¹³é¡åç©ã«æäžããå·¥çšãå«ãæ¹æ³ãæäŸãããã å³é¢ã®ç°¡åãªèª¬æ
第 1å³ã¯ã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã®ããããã·ã«ã©ãžã«ã«æ¶å»èœã é»åã¹ãã³å
±é³ŽïŒESR) ã¹ãã³ãã©ããæ³ã§æž¬å®ããçµæã瀺ããå³ã§ãããå·ŠåŽ ã®ã¹ãºã¯ãã«ã¯ãšãªã¹ãª ããŒã«ïŒæ¬çºæïŒãå³åŽã®ã¹ãºã¯ãã«ã¯ã°ã«ã³ãŒã¹ïŒå¯Ÿç
§ïŒ ã®çµæã瀺ããåã¹ãºã¯ãã«äžãå·Šå³ã® 2ã€ã®ããŒã¯ã¯ãã³ã¬ã³ãäžåäžã瀺ãã äžå€®ã® 4ã€ã®ããŒã¯ã¯ DMP0- 0Hã瀺ãã çºæãå®æœããããã®æè¯ã®åœ¢æ
æ¬çºæã§äœ¿çšããããšãªã¹ãª ããŒã« ïŒerythritol ïŒãšãª ããªã ãã ãšãª ã㪠ã âã«ã ãšãª ãããŒã«ãšåŒã°ããå ŽåãããïŒ ã¯ meso-ãšãªã¹ãª ããŒã«ã§ããã ç å³æãšããŠåžè²©ãããŠãããã®ãçšããããšãã§ããã
æ¬çºæã®ã©ãžã«ã«ã¹åã¹ã³ãžã£äžã®å©çšåœ¢æ
ã¯ç¹ã«éå®ãããã çš®ã
ã®ã©ãžã« ã«ã察象ãšããŠã çäœå
åã³çäœå€ã§å©çšããããšãã§ããã æ¬çºæã®ã©ãžã«ã« ã¹ã«ãã³ãžã£ãŒãæ¶å»å¯èœãªã©ãžã«ã«ãšããŠã¯ã ã¹äžããŒã©ãã·ãã¢äºãªã³ïŒ02â)ã ããããã·ã«ã©ãžã«ã«ïŒÎ0· )ãããããã«ã©ãã·ã©ãžã«ã«ïŒÎ00· )ãªã©ã®æŽ»æ§é
žçŽ ã® ã»ãã è質ãã«ã©ãã·ã©ãžã«ã«ã è質ã¢ã«ã³ãã·ã©ãžã«ã«ãªã©ãæããããšã㧠ãããã ãããã«éå®ãããããšã¯ãªãã 掻æ§é
žçŽ ã¯æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ ãžã£ãŒã®å¥œé©ãªæ¶å»å¯Ÿè±¡ã§ããã ç¹ã«å¥œãŸããæ¶å»å¯Ÿè±¡ã¯ã ããããã·ã«ã©ãžã«
ã«ã§ããã
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£äžãå»è¬ãšããŠçšããå Žåã«ã¯ã æå¹æåã§ã ããšãªã¹ãª ããŒã«ãçµå£çåã¯éçµå£çã«æäžããããšãã§ããã éçµå£æäžãš ããŠã¯ã æ°éå
ã çŽè
žå
ã ç®äžã çèå
ã éèå
ã åã³ç¹çŒãªã©ã®æäžçµè·¯ãæ ããããšãã§ããããšãªã¹ãª ããŒã«ãå»è¬ãšããŠåç¬ã§æäžããããšãã§ãããã ãšãªã¹ãª ããŒã«ãšãšãã«è£œå€çšæ·»å ç©ãçšããŠã é©å®ã®åœ¢æ
ã®å»è¬çµæç©ã補é ããŠæäžããŠãããã çµå£æäžã«é©ããå»è¬çµæç©ãšããŠã¯ã äŸãã°ã é å€ã é¡ ç²å€ã 现ç²å€ã æ£å€ã ã·ãããå€ã 溶液å€ã ã«ãã»ã«å€ã åã¯æžæ¿å€ãªã©ãæã ãããšãã§ããã éçµå£æäžã«é©ãã補å€ã®äŸãšããŠã¯ã äŸãã°ã 泚å°å€ã ç¹æ»Ž å€ã åžå
¥å€ã åŽé§å€ã åå€ã çµç®åžåå€ã çµç²èåžåå€ãªã©ãæããããšãã§ã ãã ãã®ãããªå»è¬çµæç©ã®ã»ãã ãšãªã¹ãª ããŒã«ãå»è¬ãšããŠããªã³ã¯å€ã å¥ åº·é£²æã æž
涌飲æã å¥åº·é£åãªã©ã«é
åããŠãããã
補å€çšæ·»å ç©ãšããŠã¯ã äŸãã°ã å®å®åå€ã çé¢æŽ»æ§å€ã å¯å¡å€ã æ»æ²¢å€ã å¯ æº¶åå€ã ç·©è¡å€ã çå³å€ã åºå€ã åžçå€ã ç¯å³å€ã çµåå€ã æžæ¿åå€ã å
æ²¢åå€ã ã³ãŒãã£ã³ã°å€ã çéŠå€ ·éŠæã 湿最å€ã 湿最調ç¯å€ã å
å¡«å€ã æ¶æ³¡å€ã ååŒå€ã æž
涌åå€ã çè²å€ã ç³è¡£å€ã ç匵åå€ã pH調ç¯å€ã è»åå€ã ä¹³åå€ã ç²çå€ã ç² çå¢åŒ·å€ã ç²çš å€ã ç²çš åå€ã çºæ³¡å€ã 賊圢å€ã åæ£å€ã åŽå°å€ã 厩å£å€ã åŽ©å£ è£å©å€ã è³éŠå€ã é²æ¹¿å€ã é²è
å€ã ä¿åå€ã ç¡çåå€ã 溶å€ã 溶解å€ã 溶解è£å© å€ã æµååå€ãªã©ãæããããšãã§ãã ãããã 2皮以äžçµã¿åãããŠçšããŠã ããã ãããã®è£œå€çšæ·»å ç©ã®å
·äœäŸã¯ã äŸãã°ã å»è¬åæ·»å ç©äºå
ž ïŒæ¥æ¬å»è¬ åæ·»å å€åäŒç·šéã è¬äºæ¥å ±ç€Ÿçºè¡ïŒ ã«èª¬æãããŠããã®ã§ã åœæ¥è
ã¯å»è¬çµæ ç©ã®åœ¢æ
ã«å¿ããŠé©å®ã®è£œå€çšæ·»å ç©ãéžæãã åœæ¥çã§æ±çšã®æ¹æ³ã«åŸã£ãŠæ æã®åœ¢æ
ã®å»è¬çµæç©ã補é ããããšãã§ããã
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãæå¹æåãšããŠå«ãå»è¬ã¯ã çäœå
ã©ãžã« ã«ãé¢äžããåçš®ã®çŸæ£ã®äºé²åã³/åã¯æ²»çã«æçšã§ããã çäœå
ã©ãžã«ã«ã® ãã¡ã 掻æ§é
žçŽ ãé¢äžããçŸæ£ãšããŠã¯ã äŸãã°ã è³ã ç¥çµçŸæ£ ïŒã¡ã«ããã€ã äžç
ãããŒãã³ãœã³ç
ãè³è¡ç®¡é害ãªã©)ãèºçŸæ£ïŒèºé
žçŽ äžæ¯ãåŒåžä¿è¿«çå矀ã
æ°ééæçãªã©)ãå¿çèè¡äžåçæµé害ãå¿çæ¢å¡ãè¡ç®¡ç³»çŸæ£ïŒåè硬åãªã©)ã æ¶å管ç²èé害 ïŒæ¶ååšæœ°çãªã©)ã èçŸæ£ã è
çŸæ£ ïŒè
çã è
äžå
šãªã©)ã çŒçŸ æ£ïŒçœå
éã 網èçŸæ£ãªã©)ã ç®èçŸæ£ïŒç®èçã å
éæçãªã©)ã ç³å°¿ç
æ§çŸæ£ã å
ç«çŸæ£ ïŒãšã€ãºã èªå·±å
ç«çŸæ£ãªã©)ã åã³çãªã©ãæããããšãã§ããã æ¬çº æã®å»è¬ã¯ã ãããã®çŸæ£ã®äºé²åã³/åã¯æ²»çã®ããã«æçšã§ããã ãããã® çŸæ£ã®ã»ãã æ¬çºæã®å»è¬ãèåé²æ¢å€ãšããŠçšããããšãå¯èœã§ããã
å»è¬ã®æäžéåã³æäžé »åºŠã¯ç¹ã«éå®ãããã äºé²åã³/åã¯æ²»çãã¹ãçŸæ£ ã®çš®é¡ã æäžçµè·¯ã æ£è
ã®å¹Žéœ¢åã³äœéã çç¶ã 䞊ã³ã«çŸæ£ã®é節床ãªã©ã®çš®ã
ã®æ¡ä»¶ã«å¿ããŠé©å®éžæããããšãå¯èœã§ããã äŸãã°ã æ人äžæ¥ãããã äœé
1 Kgã«å¯Ÿã㊠100~3ïŒ000 mgçšåºŠãäžæ¥äžååã¯æ°æ¥ããæ°é±éã«äžåã®å²å ã§æäžããããšãã§ãããã æäžéåã³æäžé »åºŠã¯ãã®ç¹å®ã®äŸã«éå®ãããã ãšã¯ãªãã ãŸãã æ¬çºæã®å»è¬ã¯ä»ã®å»è¬ã®æå¹æåãšçµã¿åãããŠçšããããš ãã§ããã
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã補å€çšæ·»å ç©ãšããŠçšããããšã«ããã å» è¬ã®æå¹æåãšæŽ»æ§é
žçŽ ã©ãžã«ã«ãšã®åå¿ã«ããæå¹æåéã®æžå°ãé²æ¢ããã ãšãã§ãã å
ãç±ãªã©ã«å¯Ÿãã補å€å®å®æ§ãé«ããããšãã§ããã äžè¬çã«ã¯ã å»è¬ã®æå¹æåãšãšãã«ã äžèšã«äŸç€ºãã補å€çšæ·»å ç©ã® 1çš®å㯠2皮以äžãšæ¬ çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãšãçšããŠå»è¬çµæç©ã補é ããã®ã奜ãŸããã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã補å€çšæ·»å ç©ãšããŠçšããå Žåã®é
åéã¯ç¹ ã«éå®ãããã æå¹æåã§ããå»è¬ã®çš®é¡ã補å€åœ¢æ
ã«å¿ããŠé©å®ã®é
åéã決 å®ããããšãã§ãããã éåžžã¯ã å»è¬ã®æå¹æåã®ééã«å¯Ÿã㊠0. 1ã1 , 000 å çšåºŠã§ããã
ãŸãã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãçäœããåé¢ Â·æ¡åãããçäœè©Šæ ã®ä¿åå€ãšããŠçšããããšãã§ããã çäœè©ŠæãšããŠã¯ã è¡æ¶²ã å°¿ãªã©ã®ã»ãã ç
ççµç¹ãæ€æ»ã®ããã®æåºçµç¹ãªã©ãæããããšãã§ãããã ãããã«éå®ã ããããšã¯ãªãã äŸãã°ã æ¡è¡ç®¡ã«æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãäºãå ã ãŠããããšã«ããã è¡æ¶²è©Šæã«å¯Ÿãã掻æ§é
žçŽ ã®åœ±é¿ãæé€ããããšãã§ãã æ£
確ãªèšåºæ€æ»åã³èšºæãå¯èœã«ãªãã
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãé£ååã¯å粧åäžã«é
åããããšã«ããã 掻æ§é
žçŽ ãªã©ã®ã©ãžã«ã«ã«ããé£ååã¯å粧åã®å質å£åãé²æ¢ããããšãã§ã ããé£åãšããŠã¯ã éèã èé¡ã éé¡ãç©é¡ãªã©ã®çé®®é£åã®ã»ãã 調çæžé£åã èåé¡ã äœã«ããªãŒçå³çµæç©ã æž
涌飲ææ°Žãªã©ã®å å·¥é£åãæããããšãã§ã ãã é£çšæ²¹ã®é
žåé²æ¢å€ãšããŠé
åããããšãå¯èœã§ããã çé®®é£ååã¯å å·¥é£ åã®çš®é¡ã¯ç¹ã«éå®ãããã çš®ã
ã®é£åã«é
åããããšãå¯èœã§ããã å å·¥é£å ã®ãã¡ã çå³ãä»å ããããšã奜é©ãªé£åã äŸãã°ã ãžã£ã ã ãã«ã¯ã ã§ãŒã°ã« ãã ãã¥ãŒã€ã³ã¬ã ã æž
涌飲ææ°Žãªã©ã«ã¯ã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã ç¹ã«å¥œé©ã«é
åããããšãã§ããã ããã«ã çå³æãšããŠçšããå Žåã«ã¯ã é£å èªäœãšããŠçšããããšãå¯èœã§ããã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã®æå¹æ åã§ãããšãªã¹ãª ããŒã«ã¯ã çäœå
ã§ä»£è¬ããã«ããã ãã€ã çµå£æäžããå Žå ã«ã¯æ¶å管å
ã§å®¹æã«åžåããããã (Oku T. , Recent Res. Devel . , Nutrition, 1, pp.1-13, 1996 )ã åŸã£ãŠã çäœå
ã®ã©ãžã«ã«ãæ¶å»ããç®çã§äœ¿çšããå Žåã« æå©ã§ããã
ãªãã æ¬æ现æžã®å®æœäŸã«ã¯ã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã®ã©ãžã«ã«æ¶ å»èœã®è©Šéšæ¹æ³ã詳现ã«é瀺ãããŠããã®ã§ã åœæ¥è
ã¯ã å®æœäŸã®å
·äœç説æã åç
§ããããšã«ããã æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãå»è¬ã®æå¹æåã è£œå€ çšæ·»å ç©ã çäœè©Šæã®ä¿åå€ã é£åã é£åæ·»å ç©ã åã¯å粧åãªã©ã®çš®ã
ã®ç®ç ã§äœ¿çšããã«ããã£ãŠã é©å®ã®äœ¿çšéã容æã«æ±ºå®ããããšãå¯èœã§ããã å®æœäŸ
以äžã æ¬çºæãå®æœäŸã«ããããã«å
·äœçã«èª¬æãããã æ¬çºæã®ç¯å²ã¯äžèš ã®å®æœäŸã«éå®ãããããšã¯ãªãã 以äžã®å®æœäŸäžã§äœ¿çšãããšãªã¹ãª ããŒã«ã¯ ããããæ¥ç ååŠæ ªåŒäŒç€Ÿè£œã§ããã
äŸ 1 ïŒ ããããã·ã«ã©ãžã«ã«æ¶å»èœ
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã®ããããã·ã«ã©ãžã«ã«æ¶å»èœãã ãã©ãã·
W ãªããŒã¹æ³ (Hal l iwel l , FEBS Lett. , 128ïŒ pp.347-352, 1981 )ã®äžéšãå€æŽãã æ¹æ³ã§æ€èšããã ããããã·ã«ã©ãžã«ã«ãšãã©ãã·ãªããŒã¹ãšã®åå¿ã§çããã ãã³ãžã¢ã«ãããïŒ MDA )ãäœã pHã§ããªã ã¬ãããŒã«é
žãšå ç±ããŠçè²ç£ç©ãç æãããã ãã®åå¿ç³»ã«ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãå
±åãããšã ããããã·ã«ã© ãžã«ã«ãæ¶å»ãã㊠MDAã®çæãæå¶ãããã æ¬è©Šéšæ¹æ³ã§ã¯ã ãšãªã¹ãª ããŒã« ã®ååšäžåã¯éååšäžã§ MDAã®çææå¶éãæ±ãã ãšãªã¹ãª ããŒã«ã®ããããã· ã«ã©ãžåã«æ¶å»èœãæ€èšããã
æçµæ¿åºŠã 50 mM ãªã³é
žç·©è¡æ¶²ïŒpH 7.0 )ã 60 mM NaCU åã³ 10 mMãã©ãã·ãª ããŒã¹ãšãªãããã«åå¿æ¶²ã調補ãããšãªã¹ãª ããŒã«ãæçµæ¿åºŠã 0.05%ã 0.5%ã åã³ 5%ãšãªãããã«å ããæåŸã« 25ãMãšãªãããã«ç¡«é
žç¬¬äžéã¢ã³ã¢ãã¥ã ã æ·»å ããŠã 37°C㧠15åéåå¿ãããã åå¿çµäºåŸã åå¿æ¶² 1 mlã« 0.6%ãã©ãã« ããäžã«é
ž 1 mlåã³ 3.5%åãªã¯ããé
¢é
ž 1 ml ãæ·»å ãã æ··åç©ãæªæããåŸ ã« 100°C㧠10åéå ç±ããã ãã®åå¿æ¶²ã 10åéæ°Žå·ãã 532 nmã§ã®åžå
床ã 枬å®ããã MDAçææå¶çïŒïŒ
)ã¯äžåŒããç®åºããïŒ 100â"(åžå
床 ïŒãšãªã¹ãª ã㌠ã«æ·»å ïŒ Ã·åžå
床 ïŒãšãªã¹ãª ããŒã«ç¡æ·»å ïŒ x l00}ã
ãã®çµæããšãªã¹ãª ããŒã« 0.05 æ¿åºŠã§ã¯ MDAæå¶ç 44.6%ã 0. 5%æ¿åºŠã§ã¯æå¶ ç 81.8%ã 5 蟲床ã§ã¯æå¶ç 88.4%ã§ããã 0.5%以äžã®æ¿åºŠã§ãšãªã¹ãª ããŒã«ãã ãããã·ã«ã©ãžã«ã«ãã»ãŒå®å
šã«æ¶å»ããŠããããšãæãããšãªã£ãã 察ç
§ãšã ãŠã°ã«ã³ãŒã¹ãçšããŠåæ§ã« MDAçææå¶çã枬å®ãããšããã 0.05%æ¿åºŠã§ã¯æ å¶ç 21.6%ã 0.5 æ¿åºŠã§ã¯æå¶ç 64.3%ã 5%æ¿åºŠã§ã¯æå¶ç 59.9%ã§ãã£ãã äŸ 2 ïŒ ããããã·ã«ã©ãžã«ã«æ¶å»èœ
ãšãªã¹ãª ããŒã«ã®ååšäžåã¯éååšäžã§ãã§ã³ãã³åå¿ïŒFenton åå¿ïŒ Ÿ02 + Fe2+ 'OH+OIT +Fe )ã«ããçºçãããããããã·ã«ã©ãžã«ã«ã«ããããªããŒã«é
ž ã®éé
žååå¿ãæ¹èµ·ãã åå¿ã®é²è¡ãçµæçã«å
±åœ¹ãžã§ã³ã®çæãšã㊠234 nm ã«ãããåžå
床ã§æž¬å®ããã
( 1 )ãªããŒã«é
žãã»ã«ã®äœæ
ãªããŒã«é
žã 30 mM (pH 11 )ã«æªæããªããå ãã IN HC1㧠pH 7ã«èª¿è£œãã 2.8 mg/ml ( 10 mM)ã®ãã»ã«ãäœæããã ãã®ãã»ã« 1 mLã« 0.8% Lubrol PX ( Sigma ç€ŸïŒ 1 mLãå ããåŸã 30 mM NaCl (pH 7)ã§å
šéã 10 mMãšãã 1 mMãã»ã«ãšã ãŠäœ¿çšããã
(2 )å
±åœ¹ãžã§ã³ã®æž¬å®
l mMãªããŒã«é
žãã»ã« 2 mLã«ã å被éšç©è³ªãæçµæ¿åºŠã lã50 mMã«ãªããã ã« 20ã100ãLã®å®¹éã§å ãã ããã« 10 mM H202 20ãLãå ããã ç¶ããŠã 16 mM FeCl2 10/LL ãå ããŠãªããŒã«é
žã®éé
žååå¿ãæ¹èµ·ããã åå¿ã®é²è¡ãçµæç ã«å
±åœ¹ãžã§ã³ã®çæãšã㊠234 nmã«ãããåžå
床å€åãåå
å
åºŠèš ïŒæ¥ç«ã 557 åäºæ¬¡æ³¢é·åå
å
床èšïŒ ãçšããŠæž¬å®ããã åå¿ã¯ 37°Cã§è¡ã£ãã 被éšç©è³ªã®ã ããã«èžçæ°Žãå ãããã®ãã³ã³ãããŒã«ãšãã ã³ã³ãããŒã«ã®åžå
床ã 100ãš ããæã®ã åžå
床ã®äœæžããã®è¢«éšç©è³ªã®é»å®³ç ïŒãšããã ãã®çµæã ãšãªã¹ãª ããŒã« 1 mMæ¿åºŠã§ã¯é»å®³ç 3.4%ã 5 mMæ¿åºŠã§ã¯é»å®³ç 18.0%ã 10 #1æ¿åºŠã§ã¯ é»å®³ç 18.2%ã 50 mMæ¿åºŠã§ã¯é»å®³ç 26.6%ã§ãã£ãã äŸ 3 ïŒ ã¯ããã·é»è²çŽ ã®å®å®å
ãšãªã¹ãª ããŒã«ã®è²çŽ å®å®åäœçšãæ€èšããã è²çŽ ãšããŠã¯ããã·é»è²çŽ ãçš ãã 10%ã®ãšãªã¹ãª ããŒã«ã®ååšäžåã¯éååšäžã«ã 宀枩ã§èå
ç¯ïŒ3, 000 lux)ã ç
§å°ããŠè²çŽ æ®åçã枬å®ããã è²çŽ æ¿åºŠã¯ 0.05 ãšãã åå¿æ¶²çµæ㯠0. 01 M ã¯ã§ã³é
žäžã¯ã§ã³é
ž Naç·©è¡æ¶²ã§ pH調æŽãããè²çŽ æ®åçã¯ãæ倧åžåæ³¢é· 440 nm ã§ã®åžå
床ã枬å®ããã¹ã¿ãŒãæã®åžå
床ã 100ãšããäžåŒããç®åºããã ïŒåžå
床 ÷ã¹ã¿ãŒãæã®åžå
åºŠïŒ X 100
ãã®çµæã PH3.5ã«ãããè²çŽ æ®åç㯠1æ¥åŸã« 60.0%ã 2æ¥åŸã« 35. 0%ã§ã〠ãããšãªã¹ãª ããŒã«ã®éååšäžã§ã¯ 1æ¥åŸã« 46.2%ã 2æ¥åŸã« 20.8%ã§ãã£ã ïŒé® å
æã®æ®åç㯠1æ¥åŸã« 89.0%ã 2æ¥åŸã« 79.2%ã§ãã£ããïŒ åæ§ã®è©Šéšã pH6.0 ã§è¡ã£ããšããããšãªã¹ãª ããŒã«ã®ååšäžã«ãããè²çŽ æ®åç㯠10æ¥åŸã« 71.6%ã 20 æ¥åŸã« 48. 5%ã§ãã£ãã ãšãªã¹ãª ããŒã«ã®éååšäžã«ãããè²çŽ æ®åç㯠10
æ¥åŸã« 57.9%ã 20æ¥åŸã« 29.5%ã§ãã£ã ïŒé®å
æã®æ®åç㯠10æ¥åŸã« 91.1°ã 20 æ°åŸã« 79.0%ã§ãã£ãã)
ãŸãã 10%ã®ãšãªã¹ãª ããŒã«ã®ååšäžåã¯éååšäžã§ãé®å
äžã« lO ppmã® Fe( I I ) ã€ãªã³ ïŒç¡«é
žç¬¬äžéã€ãªã³ïŒ ãåå¿æ¶²ïŒ0.01 ã¯ã§ã³é
žäžã¯ã§ã³é
ž Naç·©è¡æ¶²ã PH6.0 )ã«æ·»å ãã宀枩ã§é®å
äžã« 1æ¥ä¿åããåŸã®è²çŽ æ®åéã枬å®ãããšããã ãšãªã¹ãª ããŒã«ã®ååšäžã«ãããè²çŽ æ®åç㯠84.2%ã§ããã ãšãªã¹ãª ããŒã«ã® éååšäžã«ãããè²çŽ æ®åç㯠32.7%ã§ãã£ãã Fe( I I )ç¡æ·»å ã®å Žåã®æ®åç㯠90.0%ã§ãã£ãã äŸ 4 ïŒ ãªããã©ãã³ã®å®å®å
10%ã®ãšãªã¹ãª ããŒã«ã®ååšäžåã¯éååšäžã«ã 宀枩ã§ãªããã©ãã³æ°Žæº¶æ¶²
(0.004%ã 0.01 Mã¯ã§ã³é
žäžã¯ã§ã³é
ž Naç·©è¡æ¶²ã pH6.0) ã«èå
ç¯ïŒ3, 000 lux) ãç
§å°ã㊠1æ¥åŸã®ãªããã©ãã³ã®æ®åçã枬å®ããã ãšãªã¹ãª ããŒã«ã®ååšäž ã«ããããªããã©ãã³æ®åç㯠36.8%ã§ããã ãšãªã¹ãª ããŒã«ã®éååšäžã«ãã ããªããã©ãã³æ®åç㯠13.1%ã§ãã£ãã ïŒé®å
äžã§ã®æ®åç㯠104.0%ã§ã〠ããïŒ æ®åçã¯ã æ倧åžåæ³¢é· 450 nmã§ã®åžå
床ã枬å®ãã äžåŒããç®åºããã
(åžå
床 ÷ã¹å€äžåæã®åžå
åºŠïŒ X 100 äŸ 5 ïŒ ããããã·ã«ã©ãžã«ã«æ¶å»èœ
æ¬çºæã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã®ããããã·ã«ã©ãžã«ã«æ¶å»èœãã é»åã¹ã ã³å
±é³Ž ïŒESR) ã¹ãã³ãã©ããæ³ã§æ€èšããã ãã§ã³ãã³åå¿ïŒH202 +Fe2+â'0H + 0H-+Fe3+)ã§çããããããã·ã«ã©ãžã«ã«ãã ã¹ãã³åã©ããå€ãšã㊠5, 5-ãžã¡ ãã«-åãããªã³- N-ã©ãã·ã ïŒDMP0) ãçšã DMP0-0Hã¹ãã¯ãã«åŒ·åºŠãææšãšã ãã
22 mL溶液äžã§æçµæ¿åºŠã 0.034 mMç¡«é
žç¬¬äžéåã³ 8 mM DMP0ãšãªãããã«å å¿æ¶²ã調補ãã ãšãªã¹ãª ããŒã«ãæçµæ¿åºŠã 0.01%ã 0.05% 0. 1%åã³ 0.5%ãšãªã ããã«å ãã æåŸã« 0.34 mMéé
žåæ°ŽçŽ ãæ·»å ããã 宀枩æ¡ä»¶äžã åå¿ 60ç§åŸã«
枬å®ãéå§ããã ESRè£
眮ãšããŠã¯æ¥æ¬é»å JEOL JES-REIXã䜿çšããã ããã ãã·ã«ã©ãžã«ã«æ¶å»çïŒïŒ
)ã¯äžåŒããç®åºããïŒ 100â { (ãšãªã¹ãª ããŒã«æ·»å ã«ã ã DMP0-0Hã¹ãºã¯ ãã«ã®ããŒã¯ã®é«ã ÷ãã³ã¬ã³ãäžã«ãŒã®ããŒã¯ã®é«ãïŒ X100 ÷ (ãšãªã¹ãª ããŒã«ç¡æ·»å ã«ãã DMP0-0Hã¹ãã¯ãã«ã®ããŒã¯ã®é«ã ÷ãã³ã¬ã³ ããŒã«äžã®ããŒã¯ã®é«ãïŒ X100}ã 察ç
§ãšããŠã°ã«ã³ãŒã¹ãçšããŠåæ§ã®è©Šéšã è¡ã£ãã çµæãå³ 1ã«ç€ºãã DMP0- 0H ã®ã¹ãºã¯ãã«åŒ·åºŠããšãªã¹ãª ããŒã« 0.01% æ¿åºŠã§ã¯ 49.1%ã 0.05%æ¿åºŠã§ã¯ 71.4%ã 0.1%æ¿åºŠã§ã¯ 81.9%ã 0.5%æ¿åºŠã§ã¯ 92.1% æå¶ãããŠããã ã°ã«ã³ãŒã¹ã«æ¯èŒããŠé¡èãªã©ãžã«ã«æ¶å»èœãèªããããã äŸ 6 ïŒå¥œäžççåçã«ãããã©ãžã«ã«æ¶å»èœ
ãã§ã³ãã³åå¿ïŒH202 +Fe2+ .OH+OiT+Fe3 ) ã§çããããããã·ã«ã©ãžã«ã«ã« ããæ»æ»
ããã©ã ã奜äžçã®çåçã«ããããšãªã¹ãª ããŒã«ã®å¹æãæ€èšããã 0.39 mLãã³ã¯ã¹æ¶²ã«æçµæ¿åºŠãšã㊠1ã300 mMãšãªãããã«ãšãªã¹ãª ããŒã«ã æ·»å ããã ãã® 0.39 mLãã³ã¯ã¹æ¶²ã«ã 奜äžçæžæ¿ãã³ã¯ã¹æ¶² 0.10 mL (现èæ° çŽ 5X106å/ mL) ãæ·»å ãã 37°Cäžã§ 10åéã£ã³ãã¥ããŒããããã€ã㧠100 mM ç¡«é
žç¬¬äžé 0.005 mLãæ·»å 'æ··åããçŽã¡ã« 100 mMéé
žåæ°ŽçŽ 0.005 mLãæ·»å · æ··åããã 37°Cäžã§ 3æéã€ã³ãã¥ããŒãåŸã« 0.4%ããªãã³ãã«ãŒæè²æ¶²ã«ãŠæ è²ãã 奜äžçã®çæ»ãå
åŠé¡åŸ®é¡äžã§èšæž¬ããã ãã§ã³ãã³åå¿ãæ¹èµ·ããå¥œäž çã®çåç㯠33.5% (ç¡æ·»å 矀ïŒã§ãã£ãããšãªã¹ãª ããŒã« lmMã 10mMã 100 mM, åã³ 300mMã®æ·»å ã«ãã奜äžçã®çåçã¯ãããã 39.2%ã 46.5%ã 48.2%ã åã³ 63.6%ãšãªãã çåçã®äžæãèªãããã ãšãªã¹ãª ããŒã« 100 mMæ·»å 矀ã¯ç¡æ·»å 矀ãšæ¯èŒã㊠Pã 0.05(studentttest)ã§ææå·®ãèªãããã ãšãªã¹ãª ããŒã« 300 mMæ·»å 矀ã¯ç¡æ·»å 矀ãšæ¯èŒã㊠p<0.01(studentt test)ã§ææå·®ãèªããããã ç£æ¥äžã®å©çšå¯èœæ§
æ¬çºæã®ã©ãžã«ã«ã¹åã¹ã³ãžã£äžã¯å¹ççã«æŽ»æ§é
žçŽ ãªã©ã®ã©ãžã«ã«ãæ¶å»ã ãããšãã§ããã ãšãªã¹ãª ããŒã«ã¯ããã®çäœå
ã§ã¯ãšãã«ã®ãŒæºãšããŠã»ãšã
ã©å©çšãããã æåžåã æææ³ã®ç¹æ§ããã€ããšããã è¡äžã埪ç°ããŠã©ãžã«ã« ã¹ã«ãã³ãžã£ãŒãšããŠäœçšããåŸã çäœå€ã«ææ³ãããã åŸã£ãŠã æ¬çºæã®ã©ãž ã«ã«ã¹åãã³ãžã£ãŒã¯ãå»è¬ã®æå¹æåã補å€çšæ·»å ç©ãé£åæ·»å ç©ãå¥åº·é£åã åã¯å粧åãªã©ãšããŠå©çšããããšãå¯èœã§ããã
Claims
1 . ãšãªã¹ãª ããŒã«ãå«ãã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã
2 . è«æ±ã®ç¯å²ç¬¬ 1é
ã«èšèŒã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒãæå¹æåãšããŠå«ã¿ã çäœå
ã©ãžã«ã«ãé¢äžããçŸç
ã®äºé²åã³/åã¯æ²»çã«çšããããã®å»è¬ã
3 . 補å€çšæ·»å ç©åã¯çäœè©Šæã®ä¿åå€ãšããŠçšããè«æ±ã®ç¯å²ç¬¬ 1é
ã«èšèŒã® ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã
4 . é£åã é£åæ·»å ç©ã åã¯å粧åãšããŠçšããè«æ±ã®ç¯å²ç¬¬ 1é
ã«èšèŒã®ã©ãž ã«ã«ã¹åãã³ãžã£ãŒã
5 . ææ察象ã®ã©ãžã«ã«ã掻æ§é
žçŽ ã§ããè«æ±ã®ç¯å²ç¬¬ 1é
ãã第 4é
ã®ããã ã 1é
ã«èšèŒã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã
6 . ææ察象ã®ã©ãžã«ã«ãããããã·ã«ã©ãžã«ã«ã§ããè«æ±ã®ç¯å²ç¬¬ 1é
ãã第 4é
ã®ãããã 1é
ã«èšèŒã®ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒã
7 . è«æ±ã®ç¯å²ç¬¬ 2é
ã«èšèŒã®å»è¬ã®è£œé ã®ããã®ãšãªã¹ãª ããŒã«ã®äœ¿çšã
8 . çäœå
ã©ãžã«ã«ã®æ¶å»æ¹æ³ã§ãã£ãŠã æå¹éã®ãšãªã¹ãª ããŒã«ããããå«ã åºä¹³é¡åç©ã«æäžããå·¥çšãå«ãæ¹æ³ã
9 . çäœå
ã©ãžã«ã«ãé¢äžããçŸç
ã®äºé²åã³/åã¯æ²»çæ¹æ³ã§ãã£ãŠã äºé²å ã³/åã¯æ²»çæå¹éã®ãšãªã¹ãª ããŒã«ããããå«ãåºä¹³é¡åç©ã«æäžããå·¥çšã å«ãæ¹æ³ã
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/128284 | 1999-05-10 | ||
JP12828499 | 1999-05-10 | ||
JP11236319A JP2001026536A (ja) | 1999-05-10 | 1999-08-24 | ã©ãžã«ã«ã¹ã«ãã³ãžã£ãŒ |
JP11/236319 | 1999-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000067743A1 true WO2000067743A1 (fr) | 2000-11-16 |
Family
ID=26464003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/002908 WO2000067743A1 (fr) | 1999-05-10 | 2000-05-02 | Phagocyte radicalaire |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2001026536A (ja) |
WO (1) | WO2000067743A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4678079B2 (ja) * | 1999-04-06 | 2011-04-27 | 倧æ£è£œè¬æ ªåŒäŒç€Ÿ | ãªããã©ãã³é å液å€çµæç© |
JP2002097141A (ja) * | 2000-09-19 | 2002-04-02 | Nikken Chem Co Ltd | ãã¿ãã³ïœé¡å«æ氎溶液çµæç© |
JP2003267801A (ja) * | 2002-03-12 | 2003-09-25 | Pharmafoods Kenkyusho:Kk | ä¿åå€çšçµæç©åã³è©²çµæç©ãå«æããåç©ã®çŽ°èãŸãã¯èåšã®ä¿åå€ |
JP5608546B2 (ja) * | 2010-12-27 | 2014-10-15 | è±çæ ªåŒäŒç€Ÿ | æé žåå€ |
US20150104868A1 (en) * | 2012-04-22 | 2015-04-16 | Cargill, Inc. | Methods of Maintaining and Improving Biological Cell Function and Activity |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000812A1 (en) * | 1984-07-30 | 1986-02-13 | Pharmacia Ab | A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof |
JPH07233046A (ja) * | 1993-12-28 | 1995-09-05 | Kose Corp | å€çšå€ |
-
1999
- 1999-08-24 JP JP11236319A patent/JP2001026536A/ja active Pending
-
2000
- 2000-05-02 WO PCT/JP2000/002908 patent/WO2000067743A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000812A1 (en) * | 1984-07-30 | 1986-02-13 | Pharmacia Ab | A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof |
JPH07233046A (ja) * | 1993-12-28 | 1995-09-05 | Kose Corp | å€çšå€ |
Non-Patent Citations (1)
Title |
---|
P. LUND ET AL.: "Free radicals appear to affect survival of hepatocytes at 4degreesC", FREE RADICAL RES. COMMUN., vol. 1, no. 1, 1985, pages 69 - 75, XP002931242 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001026536A (ja) | 2001-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2418575C2 (ru) | ÐаМПлОпПÑПЌа Ñ Ð¿ÑОЌеМеМОеЌ ÑÑеÑОÑОÑОÑПваММПгП леÑОÑОМа О ÑпПÑПб пПлÑÑÐµÐœÐžÑ ÑакПвПй, а Ñакже кПЌпПзОÑÐžÑ ÐŽÐ»Ñ Ð¿ÑПÑОлакÑОкО ОлО леÑÐµÐœÐžÑ ÐºÐŸÐ¶ÐœÑÑ Ð·Ð°Ð±ÐŸÐ»ÐµÐ²Ð°ÐœÐžÐ¹, вклÑÑаÑÑÐ°Ñ ÑакПвÑе | |
DE69133313T2 (de) | Verwendung von Nitroxiden und Oxazolidinen zum Schutz ionisierender Strahlung und oxidativem Stress | |
ES2640777T3 (es) | Terapia anaplerótica para la enfermedad de Alzheimer | |
US20030147937A1 (en) | Use of compatible solutes as substances having free radical scavenging properties | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
Luo et al. | Acute and genetic toxicity of essential oil extracted from Litsea cubeba (Lour.) Pers. | |
US11590185B2 (en) | Antioxidant composition comprising Sargassum serratifolium extract or fraction thereof as active ingredient | |
TW201039858A (en) | Composition for alleviating ultraviolet radiation-induced damage | |
EP3243517A1 (en) | Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material | |
Babizhayev | Accumulation of lipid peroxidation products in human cataracts | |
JPH03501126A (ja) | ã¢ã«ã³ãŒã«ãžã®ç çåŠçæžæã®çºéãæå¶ããçµæç© | |
KR101740353B1 (ko) | íì°í ì¡°ì±ë¬Œ | |
WO2000067743A1 (fr) | Phagocyte radicalaire | |
JP2003012520A (ja) | æé žåå€åã³ãããå«æãã飲é£å | |
JP2010534227A (ja) | å°ãªããšãïŒã€ã®ã³ã¬ã¹ãâïŒâãšã³âïŒâãªã³ãªãã·ã èªå°äœã®é žåé²æ¢å€ãšããŠã®äœ¿çš | |
KR100265385B1 (ko) | ìíêž° ì§íì ìë°© ë° ì¹ë£ íšë¥ì ê°ë íê²œì² ì¶ì¶ë¬Œ | |
JP3977889B2 (ja) | è麊殻æœåºç©ãæå¹æåãšããè¬å€ | |
US8338488B2 (en) | Use of at least one oxime derivative of 3,5-seco-4-nor-cholestane as antioxidants | |
EP1671929A2 (en) | Process for production of aqueous colloid of graphite silica particles emitting far-infrared rays | |
Ali et al. | Hemolysis of human red blood cells by combination of riboflavin and aminophylline | |
JP2005029483A (ja) | 掻æ§é žçŽ æ¶å»å€ã䞊ã³ã«å粧æåã³é£²é£ç© | |
Belsito et al. | Safety Assessment of Mannitol, Sorbitol, and Xylitol as Used in Cosmetics | |
EP0495014A1 (en) | Novel oxidized lipoproteins and methods for their preparation | |
JP3673740B2 (ja) | 掻æ§é žçŽ æ¶å»å€ | |
JP2018503671A (ja) | ã¢ã¹ããªã¹ã¯ã¹ã°ã©ããªã¬ã³ã¹æœåºç©åã³ãã®äœ¿çš |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |